Fenben For Humans

Fenben is a broad-spectrum benzimidazole anthelmintic approved for use in several animal species. It is often used in combination with other drugs to treat a variety of opportunistic fungi including Cryptococcus neoformans, which causes meningitis in some people. It is also known to have antitumor activity in laboratory experiments against certain cancer cells, as well as a number of other conditions.

The anthelmintic has a long history of safe human use, with doses up to 1.5 g per person being effective against the parasites Ascaris and hookworm and resulting in significant egg count reductions in humans (Ann Trop Med Parasitol 1976 Jun;70(2):205-11). The drug is not well absorbed from the gut, which may limit its efficacy at high concentrations.

In a series of cell culture experiments, 2 and 24-h treatments with fenbendazole produced no toxic effect on aerobic EMT6 cells. However, fenbendazole did significantly decrease the numbers of these cells in monolayer cultures and inhibit their clonogenicity, even at concentrations close to the solubility limit of the drug. The effect of fenbendazole was more pronounced at higher concentrations and in longer treatment periods.

The drug also had therapeutic activity when administered orally to mice bearing A549 xenografts. Tumors treated with fenbendazole demonstrated significant growth inhibition and radiosensitivity. This was accompanied by a reduction in tumor vascularity, as measured by the hemoglobin content of the xenografts.

Although fenbendazole has been well-tolerated by humans in large clinical trials, its long-term safety and effectiveness in preventing human cancer is not yet established. The repurposing of veterinary drugs that show promising results in laboratories is one way to speed up the search for new cancer medicines. Nevertheless, it’s important to remember that individual results may vary and it’s crucial to consult with your physician before trying any new medication or protocol. fenben for humans

You May Also Like

More From Author

+ There are no comments

Add yours